Quotient (QTNT) Trading Down 17.2%

Quotient Ltd (NASDAQ:QTNT) shares were down 17.2% during mid-day trading on Tuesday . The stock traded as low as $4.30 and last traded at $4.39. Approximately 1,710,327 shares were traded during trading, an increase of 314% from the average daily volume of 412,805 shares. The stock had previously closed at $5.30.

Several research analysts have recently issued reports on QTNT shares. BTIG Research reaffirmed a “buy” rating and set a $12.00 price objective on shares of Quotient in a research report on Wednesday, November 1st. Jefferies Group reduced their target price on Quotient from $15.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, November 1st. Finally, Zacks Investment Research raised Quotient from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th.

The company has a debt-to-equity ratio of -5.17, a quick ratio of 0.86 and a current ratio of 1.36. The company has a market cap of $184.51, a price-to-earnings ratio of -1.41 and a beta of 1.40.

In other news, insider D J. Paul E. Cowan sold 45,000 shares of the business’s stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $4.55, for a total value of $204,750.00. Following the completion of the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $121,330.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider D J. Paul E. Cowan sold 30,197 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $4.92, for a total value of $148,569.24. Following the completion of the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at $131,196.72. The disclosure for this sale can be found here. Insiders sold a total of 175,197 shares of company stock valued at $817,319 over the last three months. Company insiders own 29.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of QTNT. New York State Common Retirement Fund purchased a new stake in Quotient during the 2nd quarter valued at approximately $101,000. Goldman Sachs Group Inc. purchased a new stake in Quotient during the 2nd quarter valued at approximately $104,000. Nationwide Fund Advisors purchased a new stake in Quotient during the 2nd quarter valued at approximately $111,000. The Manufacturers Life Insurance Company purchased a new stake in Quotient during the 2nd quarter valued at approximately $177,000. Finally, Rhumbline Advisers purchased a new stake in Quotient during the 2nd quarter valued at approximately $201,000. 47.43% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Quotient (QTNT) Trading Down 17.2%” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/11/quotient-qtnt-trading-down-17-2.html.

Quotient Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

What are top analysts saying about Quotient? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quotient and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit